Earnings ·
Reports Q3 net loss of $0.73 per share as cash drops to $199M
CAPRCapricor Therapeutics, Inc.
Capricor Therapeutics reported a third-quarter 2026 net loss of approximately $42.7 million, or $0.73 per share, compared to a $24.6 million loss in the prior-year period. Total operating expenses rose to roughly $44.7 million from $26.3 million, driven by pre-commercial activities and manufacturing scale-up, despite a workforce reduction affecting about 10% of employees. The company's cash position decreased to approximately $198.5 million as of September 30, 2026, down from $318.1 million at year-end 2025, with no shares sold under its ATM program in the first eleven months of 2026. The firm remains focused on its BLA for Deramiocel for Duchenne muscular dystrophy, with a PDUFA date set for November 22, 2026. Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases.